S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in

Abbott Laboratories Stock Forecast, Price & News

-0.80 (-0.65 %)
(As of 02/25/2021 12:00 AM ET)
Today's Range
Now: $121.58
50-Day Range
MA: $118.82
52-Week Range
Now: $121.58
Volume3.46 million shs
Average Volume5.30 million shs
Market Capitalization$215.38 billion
P/E Ratio64.33
Dividend Yield1.47%
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.
Abbott Laboratories logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
Year FoundedN/A



Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$5.45 per share
Book Value$17.70 per share


Net Income$3.69 billion


Outstanding Shares1,771,529,000
Market Cap$215.38 billion
Next Earnings Date4/15/2021 (Estimated)


Overall MarketRank

2.42 out of 5 stars

Medical Sector

13th out of 1,957 stocks

Pharmaceutical Preparations Industry

6th out of 771 stocks

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
-0.80 (-0.65 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

Is Abbott Laboratories a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 1 sell rating, 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Abbott Laboratories stock.
View analyst ratings for Abbott Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than Abbott Laboratories?

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a increase in short interest in January. As of January 29th, there was short interest totaling 11,520,000 shares, an increase of 29.4% from the January 14th total of 8,900,000 shares. Based on an average daily trading volume, of 5,100,000 shares, the days-to-cover ratio is presently 2.3 days.
View Abbott Laboratories' Short Interest

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 15th 2021.
View our earnings forecast for Abbott Laboratories

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its earnings results on Tuesday, January, 26th. The healthcare product maker reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.35 by $0.10. The healthcare product maker had revenue of $10.70 billion for the quarter, compared to analyst estimates of $9.94 billion. Abbott Laboratories had a trailing twelve-month return on equity of 18.19% and a net margin of 10.50%. The company's revenue for the quarter was up 28.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.95 EPS.
View Abbott Laboratories' earnings history

How has Abbott Laboratories' stock price been impacted by COVID-19 (Coronavirus)?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABT shares have increased by 55.7% and is now trading at $121.58.
View which stocks have been most impacted by COVID-19

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 19th. Stockholders of record on Thursday, April 15th will be given a dividend of $0.45 per share on Monday, May 17th. This represents a $1.80 annualized dividend and a dividend yield of 1.48%. The ex-dividend date is Wednesday, April 14th.
View Abbott Laboratories' dividend history

Is Abbott Laboratories a good dividend stock?

Abbott Laboratories pays an annual dividend of $1.80 per share and currently has a dividend yield of 1.47%. Abbott Laboratories has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Abbott Laboratories is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.10% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.
View Abbott Laboratories' dividend history.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY21 earnings guidance on Wednesday, January, 27th. The company provided EPS guidance of at least $5.00 for the period, compared to the Thomson Reuters consensus estimate of $4.42.

What price target have analysts set for ABT?

17 equities research analysts have issued 1-year price objectives for Abbott Laboratories' stock. Their forecasts range from $94.00 to $140.00. On average, they expect Abbott Laboratories' share price to reach $121.83 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price.
View analysts' price targets for Abbott Laboratories
or view top-rated stocks among Wall Street analysts.

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:
  • Mr. Miles D. White M.B.A., Exec. Chairman (Age 66, Pay $6.97M)
  • Mr. Robert B. Ford, CEO, Pres, COO & Director (Age 47, Pay $2.63M)
  • Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 42, Pay $1.67M)
  • Ms. Lisa D. Earnhardt, Exec. VP of Medical Devices (Age 51, Pay $1.33M)
  • Mr. Robert E. Funck Jr., Exec. VP of Fin. & CFO (Age 60)
  • Mr. Scott Michael Leinenweber, VP of Investor Relations, Licensing & Acquisitions (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • James E. Young, VP and Chief Ethics & Compliance Officer
  • Ms. Melissa Brotz, VP of Public Affairs & Corp. Marketing
  • Ms. Elaine R. Leavenworth, Sr. VP and Chief Marketing & External Affairs Officer (Age 62)

What is Robert Ford's approval rating as Abbott Laboratories' CEO?

183 employees have rated Abbott Laboratories CEO Robert Ford on Glassdoor.com. Robert Ford has an approval rating of 89% among Abbott Laboratories' employees.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.53%), Morgan Stanley (1.51%), Northern Trust Corp (1.49%), Bank of New York Mellon Corp (1.20%), Wells Fargo & Company MN (1.13%) and FMR LLC (1.02%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Michelle Kumbier, Miles D White, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Boston Partners, Boston Partners, Sumitomo Mitsui Trust Holdings Inc., Fort Pitt Capital Group LLC, DSM Capital Partners LLC, and Northern Trust Corp. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael J Pederson, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories
or view top insider-selling stocks.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Assenagon Asset Management S.A., Healthcare of Ontario Pension Plan Trust Fund, Amundi Pioneer Asset Management Inc., Swedbank, First Trust Advisors LP, and Bank of New York Mellon Corp. Company insiders that have bought Abbott Laboratories stock in the last two years include Michelle Kumbier, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories
or or view top insider-buying stocks.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $121.58.

How much money does Abbott Laboratories make?

Abbott Laboratories has a market capitalization of $215.38 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis.

How many employees does Abbott Laboratories have?

Abbott Laboratories employs 107,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is www.abbott.com.

Where are Abbott Laboratories' headquarters?

Abbott Laboratories is headquartered at 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.